pharmaphorum April 5, 2024
Johnson & Johnson has reached a deal to acquire Shockwave Medical for around $13.1 billion, expanding its position in medical devices used to treat heart disease.
J&J has agreed to pay $335 per share in cash for Santa Clara, California-based Shockwave, which specialises in intravascular lithotripsy (IVL) technology for the treatment of calcified blood vessels in coronary artery disease (CAD) and peripheral artery disease (PAD).
IVL is a minimally invasive procedure that uses sound waves to destroy the calcified lesions, which can reduce blood flow and cause pain or heart attack. At the moment, Shockwave is the only company with IVL systems on the market, generating $730 million in revenues in 2023, up 49% on the prior year.
Shockwave recently...
Today's Sponsors
Today's Sponsor